Bluejay Diagnostics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$0.31next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Third Quarter 2026 Corporate Update and Financial Results | 13 Nov 2026 |
Monitoring Framework
Key Performance Indicators
SYMON-II Pivotal Clinical Trial Patient Enrollment Quarterly680.0
Cash and Cash Equivalents Quarterly3.7MTarget: At least $30 million of capital raised between 2025 and 2027
Symphony Cartridge Production Capacity Quarterly10MTarget: Sufficient supply capacity for commercial launch
Watch Items
- SYMON-II Pivotal Clinical Trial Enrollment CompletionTrigger: 750 patients enrolledAction: Transition to data analysis, lock the database, and prepare the statistical analysis plan for primary endpoints.
- Symphony Cartridge Manufacturing Validation with Sanyoseiko and ArgonautTrigger: Completion of analytical and clinical validation of cartridgesAction: Verify that manufactured cartridges meet FDA requirements for submission and commercial production.
- FDA 510(k) Regulatory Submission for Symphony IL-6 TestTrigger: Submission of 510(k) application to the FDAAction: Engage with FDA during the review process to secure regulatory clearance for sepsis triage and monitoring.
Research as of 20 Jun 2026